Ibuprofen in children with cystic fibrosis: Pharmacokinetics and adverse effects*

https://doi.org/10.1016/S0022-3476(05)82218-8Get rights and content

Antiinflammatory therapy with ibuprofen has been proposed to retard the progression of lung disease in cystic fibrosis (CF). The pharmacokinetics and toxicity of ibuprofen were investigated in a randomized, double-blin, placebo-controlled, 3-month dose-escalation study in 19 children with CF, 6 to 12 years of age. The subjects received orally and twice daily 300 mg of drug during the first month, 400 mg in the second month, and 600 mg in the third month. Ibuprofen pharmacokinetics and evaluation for adverse effects were performed at the beginning and end of each month. The dose of ibuprofen was increased if peak plasma concentration (Cmax) was<50 μg/ml. To preserve the blind nature of the study, the dose in matched subjects taking placebo was also increased. The subjects randomly assigned to receive ibuprofen (n=13) completed 26 months of treatment; placebo subjects (n=5) completed 12 months. With dose escalation, Cmax and the area under the concentration-time curve from zero to infinity significantly increased (p<0.01). The pharmacokinetics of ibuprofen in 13 children with CF who received 13.4±4.1 mg/kg (mean ±SD) were compared with those in four healthy children who received a similar dose. Peak plasma concentration (48±17 μg/ml) was decreased by 27% (p=0.06), the area under the concentration-time curve (6.1±1.7 mg·min/ml) was decreased by 46% (p<0.001), apparent total clearance (2.3±0.6 ml/min ·kg−1) was increased by 77% (p<0.01), and apparent volume of distribution during terminal phase (291±91 ml/kg) was increased by 84% (p=0.01) in the children with CF. Time to Cmax (66±20 minutes) and elimination half-life (92±27 minutes) were not significantly different. No subjects were withdrawn from the study because of side effects. No adverse effects could be attributed to ibuprofen. Thus ibuprofen administration has no significant toxic effects, but Cmax will need to be monitored for effective dosing in patients with CF.

References (41)

  • KnoppertDC et al.

    Cystic fibrosis: enhanced theophylline metabolism may be linked to the disease

    Clin Pharmacol Ther

    (1988)
  • KnudsonRJ et al.

    Changes in the normal maximal expiratory flow-volume curve with growth and aging

    Am Rev Respir Dis

    (1983)
  • BarnhartER

    Physicians' desk reference

  • MaderazoEG et al.

    Inhibition of human polymorphonuclear leukocyte cell responses by ibuprofen

    J Pharm Sci

    (1984)
  • FlynnPJ et al.

    Ibuprofen inhibits granulocyte responses to inflammatory mediators: a proposed mechanism for reduction of experimental myocardial infarct size

    Inflammation

    (1984)
  • MillsRFN et al.

    The metabolism of ibuprofen

    Xenobiotica

    (1973)
  • LeederJS et al.

    Ceftazidime disposition in acute and stable cystic fibrosis

    Clin Pharmacol Ther

    (1984)
  • SimilaS et al.

    Oral antipyretic therapy evaluation of ibuprofen

    Scand J Rheumatol

    (1976)
  • ShethUK et al.

    Measurement of antipyretic activity of ibuprofen and paracetamol in children

    J Clin Pharmacol

    (1980)
  • Keinanen-KiukaanniemaS et al.

    Oral antipyretic therapy evaluation of the propionic acid derivatives ibuprofen, ketoprofen, fenoprofen and naproxen

    Padiatr Padol

    (1980)
  • Cited by (0)

    *

    Supported by Cystic Fibrosis Foundation and National Institutes of Health grants P30-DK27651, T32-HL07415, and MO1 RR-00080.

    View full text